{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:32:31Z","timestamp":1787668351320,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate the prognostic value of preoperative serum albumin to globulin ratio (AGR) in patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of bladder tumor (TURB) with or without intravesical therapy (IVT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>We retrospectively reviewed 1,096 consecutive patients with NMIBC. Levels of albumin and globulin were obtained before TURB and used to calculate the preoperative AGR level. Multivariable Cox regression analyses were performed to assess the prognostic effect of preoperative AGR on oncologic outcomes. Subgroup analyses were performed in patients based on the European Association of Urology (EAU) risk groups for NMIBC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Low AGR levels were observed in 389 (35.5%) patients. The median follow-up was 63.7\u00a0months (IQR 25.3\u2013111). On multivariable Cox regression analysis, low AGR was associated with increased risk of progression to muscle-invasive BCa (MIBC) (HR 1.81, 95% CI 1.22\u20132.68, <jats:italic>P<\/jats:italic>\u2009=\u20090.003). The addition of AGR only minimally improved the discrimination ability of a base model that included established clinicopathologic features (C-index\u2009=\u20090.7354 vs. C-index\u2009=\u20090.7162). Low preoperative AGR was not significantly associated with the risk of disease recurrence (<jats:italic>P<\/jats:italic>\u2009=\u20090.31). In subgroup analyses based on patients\u2019 EAU risk groups, low preoperative AGR was not associated with recurrence-free survival (RFS) (<jats:italic>P<\/jats:italic>\u2009=\u20090.59) or progression-free survival (PFS) (<jats:italic>P<\/jats:italic>\u2009=\u20090.22) in any of the risk groups. Additionally, in patients treated with Bacillus Calmette\u2013Guerin (BCG) for intermediate- or high-risk NMIBC, low AGR failed to predict disease recurrence or progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Preoperative serum AGR levels independently predicted the risk of disease progression in patients with NMIBC. However, it was not found to be associated with either RFS or PFS in NMIBC patients based on their EAU risk group. This marker seems to have a limited role in NMIBC at the present time. However, further research is needed to investigate this marker in combination with other systemic inflammatory markers to help improve prediction in this heterogeneous group of patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-020-03586-1","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T09:03:21Z","timestamp":1611651801000},"page":"3345-3352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-6953","authenticated-orcid":false,"given":"Fahad","family":"Quhal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Sari Motlagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Mostafaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Schuettfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Enikeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abufaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"key":"3586_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I et al (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71:96","journal-title":"Eur Urol"},{"key":"3586_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comperat EM et al (2019) European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 Update. Eur Urol 76:639","journal-title":"Eur Urol"},{"key":"3586_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","volume":"67","author":"P Gontero","year":"2015","unstructured":"Gontero P, Sylvester R, Pisano F et al (2015) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67:74","journal-title":"Eur Urol"},{"key":"3586_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/bjc.2013.372","volume":"109","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Kent M, Kluth L et al (2013) Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 109:1460","journal-title":"Br J Cancer"},{"key":"3586_CR5","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","volume":"176","author":"SF Shariat","year":"2006","unstructured":"Shariat SF, Karakiewicz PI, Palapattu GS et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414","journal-title":"J Urol"},{"key":"3586_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","volume":"45","author":"BP Schrier","year":"2004","unstructured":"Schrier BP, Hollander MP, van Rhijn BW et al (2004) Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45:292","journal-title":"Eur Urol"},{"key":"3586_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.eururo.2018.11.052","volume":"75","author":"M Abufaraj","year":"2019","unstructured":"Abufaraj M, Foerster B, Schernhammer E et al (2019) Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes. Eur Urol 75:649","journal-title":"Eur Urol"},{"key":"3586_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bju.14417","volume":"123","author":"A Mari","year":"2019","unstructured":"Mari A, Kimura S, Foerster B et al (2019) A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int 123:11","journal-title":"BJU Int"},{"key":"3586_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","volume":"57","author":"HM Fritsche","year":"2010","unstructured":"Fritsche HM, Burger M, Svatek RS et al (2010) Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57:300","journal-title":"Eur Urol"},{"key":"3586_CR10","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1464-410X.2010.09628.x","volume":"107","author":"RS Svatek","year":"2011","unstructured":"Svatek RS, Shariat SF, Novara G et al (2011) Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 107:898","journal-title":"BJU Int"},{"key":"3586_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.urolonc.2010.02.011","volume":"28","author":"SF Shariat","year":"2010","unstructured":"Shariat SF, Lotan Y, Vickers A et al (2010) Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 28:389","journal-title":"Urol Oncol"},{"key":"3586_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00345-018-2503-4","volume":"37","author":"F Soria","year":"2019","unstructured":"Soria F, Krabbe LM, Todenh\u00f6fer T et al (2019) Molecular markers in bladder cancer. World J Urol 37:31","journal-title":"World J Urol"},{"key":"3586_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000369357","volume":"94","author":"BJ Schmitz-Dr\u00e4ger","year":"2015","unstructured":"Schmitz-Dr\u00e4ger BJ, Droller M, Lokeshwar VB et al (2015) Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO\/ICUD consensus. Urol Int 94:1","journal-title":"Urol Int"},{"key":"3586_CR14","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/S0090-4295(03)00236-X","volume":"61","author":"SF Shariat","year":"2003","unstructured":"Shariat SF, Kim J, Raptidis G et al (2003) Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61:1140","journal-title":"Urology"},{"key":"3586_CR15","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/01.ju.0000043638.89552.ed","volume":"169","author":"SF Shariat","year":"2003","unstructured":"Shariat SF, Kim JH, Ayala GE et al (2003) Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 169:938","journal-title":"J Urol"},{"key":"3586_CR16","doi-asserted-by":"publisher","first-page":"3083267","DOI":"10.1155\/2017\/3083267","volume":"2017","author":"MJ Mao","year":"2017","unstructured":"Mao MJ, Wei XL, Sheng H et al (2017) Clinical significance of preoperative albumin and globulin ratio in patients with gastric cancer undergoing treatment. Biomed Res Int 2017:3083267","journal-title":"Biomed Res Int"},{"key":"3586_CR17","doi-asserted-by":"crossref","unstructured":"Li J., Wang Y., Wu Y. et al. Prognostic value of pretreatment albumin to globulin ratio in lung cancer: a meta-analysis. Nutr Cancer: 1, 2020","DOI":"10.1080\/01635581.2020.1737155"},{"key":"3586_CR18","doi-asserted-by":"publisher","first-page":"179.e19","DOI":"10.1016\/j.urolonc.2018.11.005","volume":"37","author":"S Kimura","year":"2019","unstructured":"Kimura S, Soria F et al (2019) Prognostic value of modified glasgow prognostic score in non-muscle-invasive bladder cancer. Urol Oncol 37:179.e19","journal-title":"Urol Oncol"},{"key":"3586_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ (1950) Index for rating diagnostic tests. Cancer 3:32","journal-title":"Cancer"},{"key":"3586_CR20","doi-asserted-by":"publisher","first-page":"e755","DOI":"10.1016\/j.clgc.2017.03.007","volume":"15","author":"D D'Andrea","year":"2017","unstructured":"D\u2019Andrea D, Moschini M, Gust K et al (2017) Prognostic role of neutrophil-to-lymphocyte ratio in primary non-muscle-invasive bladder cancer. Clin Genitourin Cancer 15:e755","journal-title":"Clin Genitourin Cancer"},{"key":"3586_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.euf.2015.03.001","volume":"2","author":"I Lucca","year":"2016","unstructured":"Lucca I, Jichlinski P, Shariat SF et al (2016) The neutrophil-to-lymphocyte ratio as a prognostic factor for patients with urothelial carcinoma of the bladder following radical cystectomy: validation and meta-analysis. Eur Urol Focus 2:79","journal-title":"Eur Urol Focus"},{"key":"3586_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.euo.2018.06.006","volume":"1","author":"F Cantiello","year":"2018","unstructured":"Cantiello F, Russo GI, Vartolomei MD et al (2018) Systemic inflammatory markers and oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Eur Urol Oncol 1:403","journal-title":"Eur Urol Oncol"},{"key":"3586_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.urology.2016.06.007","volume":"95","author":"I Lucca","year":"2016","unstructured":"Lucca I, Hofbauer SL, Leitner CV et al (2016) Development of a preoperative nomogram incorporating biomarkers of systemic inflammatory response to predict nonorgan-confined urothelial carcinoma of the bladder at radical cystectomy. Urology 95:132","journal-title":"Urology"},{"key":"3586_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejso.2013.08.023","volume":"40","author":"E Xylinas","year":"2014","unstructured":"Xylinas E, Robinson BD, Kluth LA et al (2014) Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol 40:121","journal-title":"Eur J Surg Oncol"},{"key":"3586_CR25","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/01.ju.0000080401.85145.ee","volume":"170","author":"SF Shariat","year":"2003","unstructured":"Shariat SF, Matsumoto K, Kim J et al (2003) Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol 170:985","journal-title":"J Urol"},{"key":"3586_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.juro.2009.02.125","volume":"182","author":"SF Shariat","year":"2009","unstructured":"Shariat SF, Bolenz C, Godoy G et al (2009) Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 182:78","journal-title":"J Urol"},{"key":"3586_CR27","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1002\/1097-0142(20011215)92:12<2985::AID-CNCR10175>3.0.CO;2-5","volume":"92","author":"SF Shariat","year":"2001","unstructured":"Shariat SF, Kim JH, Andrews B et al (2001) Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 92:2985","journal-title":"Cancer"},{"key":"3586_CR28","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/S0022-5347(05)65348-7","volume":"167","author":"B Andrews","year":"2002","unstructured":"Andrews B, Shariat SF, Kim JH et al (2002) Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 167:1475","journal-title":"J Urol"},{"key":"3586_CR29","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.eururo.2007.09.036","volume":"52","author":"K Bensalah","year":"2007","unstructured":"Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52:1601","journal-title":"Eur Urol"},{"key":"3586_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466","journal-title":"Eur Urol"},{"key":"3586_CR31","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182:2195","journal-title":"J Urol"},{"key":"3586_CR32","doi-asserted-by":"publisher","first-page":"e655","DOI":"10.1016\/j.clgc.2017.12.013","volume":"16","author":"N Niwa","year":"2018","unstructured":"Niwa N, Matsumoto K, Ide H et al (2018) Prognostic value of pretreatment albumin-to-globulin ratio in patients with non-muscle-invasive bladder cancer. Clin Genitourin Cancer 16:e655","journal-title":"Clin Genitourin Cancer"},{"key":"3586_CR33","doi-asserted-by":"publisher","first-page":"8.e17","DOI":"10.1016\/j.urolonc.2017.08.027","volume":"36","author":"M Rieken","year":"2018","unstructured":"Rieken M, Shariat SF, Kluth L et al (2018) Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urol Oncol 36:8.e17","journal-title":"Urol Oncol"},{"key":"3586_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","volume":"60","author":"J Fernandez-Gomez","year":"2011","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin: external validation of the EORTC risk tables. Eur Urol 60:423","journal-title":"Eur Urol"},{"key":"3586_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","volume":"27","author":"SP Lerner","year":"2009","unstructured":"Lerner SP, Tangen CM, Sucharew H et al (2009) Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 27:155","journal-title":"Urol Oncol"},{"key":"3586_CR36","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, Bohle A et al (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 34:1935","journal-title":"J Clin Oncol"},{"key":"3586_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/MOU.0000000000000593","volume":"29","author":"MR Hassler","year":"2019","unstructured":"Hassler MR, Shariat SF, Soria F (2019) Salvage therapeutic strategies for Bacillus Calmette-Guerin failure. Curr Opin Urol 29:239","journal-title":"Curr Opin Urol"},{"key":"3586_CR38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","volume":"73","author":"AM Kamat","year":"2018","unstructured":"Kamat AM, Li R, O\u2019Donnell MA et al (2018) Predicting response to intravesical bacillus calmette-gu\u00e9rin immunotherapy: are we there yet? Sys Rev Eur Urol 73:738","journal-title":"Sys Rev Eur Urol"},{"key":"3586_CR39","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2217\/imt-2019-0083","volume":"11","author":"SF Shariat","year":"2019","unstructured":"Shariat SF, Enikeev DV, Mostafaei H (2019) Six essential conditions for bladder-sparing strategies in bacillus Calmette-Gu\u00e9rin unresponsive bladder cancer. Immunotherapy 11:1083","journal-title":"Immunotherapy"},{"key":"3586_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.semcancer.2011.12.005","volume":"22","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR, Mantovani A (2012) Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 22:33","journal-title":"Semin Cancer Biol"},{"key":"3586_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1515\/CCLM.2005.156","volume":"43","author":"M Rasouli","year":"2005","unstructured":"Rasouli M, Okhovatian A, Enderami A (2005) Serum proteins profile as an indicator of malignancy: multivariate logistic regression and ROC analyses. Clin Chem Lab Med 43:913","journal-title":"Clin Chem Lab Med"},{"key":"3586_CR42","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s00384-013-1748-z","volume":"28","author":"B Azab","year":"2013","unstructured":"Azab B, Kedia S, Shah N et al (2013) The value of the pretreatment albumin\/globulin ratio in predicting the long-term survival in colorectal cancer. Int J Colorectal Dis 28:1629","journal-title":"Int J Colorectal Dis"},{"key":"3586_CR43","doi-asserted-by":"publisher","first-page":"6449","DOI":"10.7314\/APJCP.2014.15.15.6449","volume":"15","author":"AO Duran","year":"2014","unstructured":"Duran AO, Inanc M, Karaca H et al (2014) Albumin-globulin ratio for prediction of long-term mortality in lung adenocarcinoma patients. Asian Pac J Cancer Prev 15:6449","journal-title":"Asian Pac J Cancer Prev"},{"key":"3586_CR44","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.amjsurg.2013.03.007","volume":"206","author":"BN Azab","year":"2013","unstructured":"Azab BN, Bhatt VR, Vonfrolio S et al (2013) Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. Am J Surg 206:764","journal-title":"Am J Surg"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-020-03586-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03586-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T16:04:46Z","timestamp":1674921886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-020-03586-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3586"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03586-1","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,26]]},"assertion":[{"value":"13 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving Human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}